Navigation Links
PhRMA Statement on Proposed Changes to Medicaid in Louisiana
Date:9/12/2012

WASHINGTON, Sept. 12, 2012 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on proposed changes to Medicaid in Louisiana:

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO )

"Seeking new approaches to coordinate care for Medicaid and LaCHIP recipients is critically important. However, without proper protections for patients, the Louisiana Department of Health and Hospitals' (DHH) plans could put vulnerable Medicaid patients at risk. New laws passed by the Louisiana legislature and signed by Governor Bobby Jindal in 2011 and 2012 protect patients by providing a balance between the need to address increasing budget considerations and ensuring patient safety. DHH's proposal indicates that those patient protections, which were designed to curb overzealous rationing of care under prior authorization and step therapy schemes, may be in jeopardy. PhRMA is concerned that it may leave final prescriptive authority with insurance companies rather than physicians.

"The aim of integrating benefits should be to increase patient adherence to prescribed medicines. Greater adherence to prescription regimens improves the quality of health outcomes and reduces medical costs.

"In addition to maintaining the patient safety protections approved by the legislature in 2011 and 2012, rules promulgated by DHH should include access to a range of prescription medicines, including, where available, a minimum of two brand-name treatments; guaranteed access to successful therapies at least until the time a physician is able to find another equally beneficial medication; and a transparent review system for all formulary management tools. However, it should be noted that the DHH plans are moving very rapidly, which raises additional concerns about having adequate time to ensure patients will receive needed protections and quality of care is upheld.

"It is important that any plan to coordinate care for Medicaid patients not inadvertently stint on patients' access to needed treatments. Not only do such policies harm patient health, but they can run counterproductive to lowering medical expenses. For example, Harvard research found that limits on the number of Medicaid prescriptions reimbursed for chronically ill elderly and disabled people resulted in a 35 percent reduction in the use of clinically essential medicines and a 200 percent increase in the use of medical services such as skilled nursing facility and emergency mental health services, exceeding the cost of medicines.

"Limiting the number of medicines a patient can receive is the wrong approach. Not every patient responds to every medicine in the same way, making it vitally important for physicians and patients to have a choice among multiple therapies when deciding on the best treatment plan.

"We look forward to working with Secretary Greenstein and the Louisiana DHH to ensure that state Medicaid patients receive the high quality health care coverage they deserve."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org 
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org 
For information on ensuring the flow of medicines during public health emergencies, visit: http://www.rxresponse.org

 


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers and Patient Advocates Honored with PhRMA Award
2. National Press Club to Host "NEWSMAKER" with PhRMA CEO to Discuss Policy, Budget Threats to Biopharmaceutical Research
3. Heart Failure Society of America And The American Association of Heart Failure Nurses Release Joint Statement
4. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. International Isotopes Inc. Announces Nuclear Regulatory Commission Approval Of The Final Environmental Impact Statement For The Planned Depleted Uranium De-Conversion And Fluorine Extraction Processing Facility
6. Johnson Health Tech Statement on Lance Armstrong
7. CRE Statement on "Inherent Reasonableness" for Retail Pharmacy Diabetic Supplies
8. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
9. Lilly Statement on Affordable Care Act Ruling by Supreme Court
10. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
11. Lilly Statement on PDUFA Vote by Senate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted ... expected to grow at a CAGR of 6.0% during ... larger share in the global market between the two ... the hospital segment accounted for the highest share in ... peripheral I.V. catheter market is witnessing high growth rate, ...
(Date:1/23/2017)... Jan. 23, 2017  HOPE BIOSCIENCES announced today ... develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through ... pharmaceutical company. nuc -Gemcitabine consists ... surface nucleolin found on many cancer cells, and ... (antibody drug conjugates) or SMDCs (small molecule drug ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American ... particularly good news for prostate cancer patients: incidents of cancer is down as is ... report the cancer death rate has dropped from its peak of 215.1 in 1991 ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... officially unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience ... Taza Agua is renowned for introducing the world’s first untouched bottled water purposed ...
(Date:1/24/2017)... ... 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an ... gossip, prostitution, adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” ... David Coats. In September of 1983, they flew to Haiti to focus on ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... “The Octagon ... balance. “The Octagon of Spiritual Balances” is the creation of published author, Pastor Bernard ... Bernard J. Weathers holds a bachelor degree in religious education and a master degree ...
Breaking Medicine News(10 mins):